Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.
Recce Pharmaceuticals Ltd has announced an amendment to its Securities Trading Policy in line with ASX Listing Rule 12.10, with updated details available on their website. The company, known for developing synthetic anti-infectives aimed at combating antibiotic-resistant superbugs and viral pathogens, has its innovative RECCE compounds recognized by the WHO and granted favorable designations by the FDA. Recce maintains an automated manufacturing process to support ongoing clinical trials of its broad-spectrum anti-infectives targeting unmet medical needs.
For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.
